Stocktoria
INOVIO PHARMACEUTICALS, INC. INO
INOVIO PHARMACEUTICALS, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $65,343 | $217,756 | $832,010 | $10.3M | $1.8M | $7.4M | $4.1M | $30.5M | $42.2M | $35.4M |
| R&D expense | $54.2M | $75.6M | $86.7M | $187.7M | $249.2M | $94.2M | $88.0M | $95.3M | $98.6M | $88.7M |
| Operating income | -$86.8M | -$112.4M | -$143.9M | -$267.6M | -$301.2M | -$124.1M | -$111.1M | -$94.1M | -$83.6M | -$76.2M |
| Interest expense | — | — | $1.2M | $1.3M | $1.9M | $8.7M | $7.9M | $0 | $25,933 | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | -$257,335 | $2.2M | $0 | $0 |
| Net income | -$84.9M | -$107.3M | -$135.1M | -$279.8M | -$303.7M | -$166.4M | -$119.4M | -$97.0M | -$88.2M | -$73.7M |
| EPS (diluted) | $-1.81 | $-3.95 | $-6.09 | $-14.07 | $-17.45 | $-1.07 | $-1.21 | $-1.05 | $-1.09 | $-1.01 |
| Operating cash flow | -$88.6M | -$104.1M | -$124.4M | -$216.2M | -$215.7M | -$178.0M | -$97.9M | -$73.6M | -$63.2M | -$62.6M |
| Free cash flow | -$88.9M | -$104.6M | -$124.7M | -$217.2M | -$216.9M | -$179.5M | -$98.8M | -$75.6M | -$73.5M | -$65.3M |
| Cash & equivalents | $44.3M | $65.8M | $14.3M | $46.3M | $71.1M | $250.7M | $22.2M | $23.7M | $23.8M | $19.1M |
| Total assets | $74.3M | $113.2M | $171.0M | $348.5M | $495.9M | $539.8M | $144.0M | $131.1M | $187.2M | $173.7M |
| Total liabilities | $50.2M | $44.7M | $53.6M | $126.2M | $96.3M | $78.6M | $138.5M | $44.1M | $44.8M | $50.3M |
| Shareholders' equity | $24.1M | $68.5M | $117.3M | $222.4M | $399.7M | $461.1M | $5.4M | $87.0M | $142.5M | $123.4M |
Growth · year-over-year · Revenue CAGR -50.3%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -70.0% | -73.8% | -91.9% | +478.2% | -76.1% | +80.2% | -86.5% | -27.8% | +19.4% | -12.8% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.